- Home
- CWEN vs PCVX Comparison
CWEN vs PCVX Comparison
Compare CWEN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | PCVX |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 6.0B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CWEN | PCVX |
|---|---|---|
| Price | $34.00 | $46.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $39.14 | ★ $101.67 |
| AVG Volume (30 Days) | 971.0K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | ★ 125.75 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $1,375,000,000.00 | N/A |
| Revenue This Year | $3.65 | N/A |
| Revenue Next Year | $14.78 | N/A |
| P/E Ratio | $14.44 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $24.40 | $27.66 |
| 52 Week High | $36.89 | $94.60 |
Technical Indicators
Market Signals| Indicator | CWEN | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 51.97 |
| Support Level | $34.69 | $43.78 |
| Resistance Level | $36.70 | $48.11 |
| Average True Range (ATR) | 0.73 | 1.99 |
| MACD | -0.41 | -0.49 |
| Stochastic Oscillator | 9.12 | 42.99 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.